Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 33313656.
- Also identified by DOI 10.1093/cid/ciaa1847 and PMC identifier 8678443.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurred after 11 of 12 treatment courses. However, microbiologic relapse was observed after 11 of 12 treatment courses, notably without emergence of resistance.
Medical subject headings
- Achromobacter denitrificans
- Cystic Fibrosis
- Gram-Negative Bacterial Infections